Latest News and Press Releases

The Opticyte Tears program uses patients’ blood serum to create Autologous Serum Tears from the convenience of their homes.

MONTREAL, Dec. 15, 2021 (GLOBE NEWSWIRE) -- NTC Srl, R&D driven pharmaceutical company with headquarters in Italy, and I-MED Pharma Inc., a Canadian company specializing in dry eye diagnosis and...

MONTREAL, Nov. 09, 2021 (GLOBE NEWSWIRE) -- With the recent expansion into the United States, I-MED Pharma USA is proud to announce the appointment of Michelle Schnabel to the role of VP Business...

MONTREAL, Nov. 05, 2021 (GLOBE NEWSWIRE) -- I-MED Pharma USA is bringing the world’s most innovative dry eye product portfolio to the U.S. market. Their uniquely formulated line of ocular surface...

MONTREAL, Nov. 10, 2020 (GLOBE NEWSWIRE) -- I-MED Pharma Inc., a Canadian company specializing in dry eye diagnosis and management, announces the launch of tearcheck®, a new Health Canada approved...

MONTREAL, Feb. 03, 2020 (GLOBE NEWSWIRE) -- I-MED Pharma Inc., a Canadian company specializing in dry eye diagnosis and management, announced today that the company has plans to launch its newest,...

MONTREAL, Oct. 02, 2018 (GLOBE NEWSWIRE) -- I-MED Pharma Inc., a Canadian company specializing in dry eye diagnosis and management, is pleased to announce the signing of an exclusive agreement with...

MONTREAL, July 23, 2018 (GLOBE NEWSWIRE) -- I-MED Pharma Inc., a Canadian company specializing in dry eye diagnosis and management, is pleased to announce the signing of an exclusive agreement with...

MONTRÉAL, 24 mai 2018 (GLOBE NEWSWIRE) -- I-MED Pharma inc., une entreprise canadienne spécialisée dans le diagnostic et la prise en charge de la sécheresse oculaire, est ravie d’annoncer...

MONTREAL, May 24, 2018 (GLOBE NEWSWIRE) -- I-MED Pharma Inc., a Canadian company specializing in dry eye diagnosis and management, is pleased to announce the signing of a Canadian distribution...